Passage Bio, Inc. (PASG) M&A Call Prepared Remarks Transcript

Passage Bio announced a definitive all-stock merger agreement with Remix Therapeutics, alongside a concurrent private placement financing led by biotechnology investors that is expected to close immediately before the merger. Management said the deal followed a comprehensive strategic review and is intended to create value for Passage shareholders. The transaction meaningfully shifts the company’s profile toward a combined biotech platform with financing support for Remix’s pipeline programs.

Analysis

This is less a clean upside M&A story than a capital-structure reset that transfers optionality from a stranded microcap cash shell to a better-funded private biotech platform. The financing sponsor list matters more than the headline merger: a committed biotech syndicate implies the market is underwriting development risk that public PASG holders were unlikely to finance on their own, which should tighten the discount to deal value and reduce near-term blowup risk. The first-order winner is the combined company if the private placement truly closes on time; the second-order winner may be other preclinical/early clinical gene-therapy or RNA-editing names that can now point to a viable public-market path via reverse merger plus private money.

The main risk is execution over the next 1-6 months, not strategic logic. All-stock transactions are highly sensitive to relative trading levels, so any weakness in the pro forma equity, financing slippage, or a widening risk-off tape can reprice the implied deal value quickly. There is also a structural overhang: if the market suspects the combined entity is being financed at a valuation below public expectations, legacy PASG holders may sell into strength, capping upside until deal close and possibly creating a post-close technical reset.

The contrarian view is that this may be a better event for deal-arb than for directional biotech bulls. The market is likely to give some premium for a “survival” transaction, but the durable value creation depends entirely on clinical differentiation of the new pipeline, which is still a years-long proof point. If the merger closes, the right read may be that management has bought time and solvency, not necessarily that fundamental value has been created yet.

Key Decisions for Investors

• Long PASG common only as a short-dated merger-arb expression, sized small and focused on the spread to closing; risk/reward improves only if the financing is contractually locked and termination risk is low.
• Pair: long PASG / short a basket of weaker cash-burning small-cap biotech names over the next 1-3 months to isolate the financing/financing-access premium; this works best if the market starts rewarding balance-sheet survival over pure story risk.
• If liquidity allows, buy short-dated call spreads in PASG into deal-closure confirmation; upside is capped by all-stock dilution, so structure should target a defined spread compression rather than open-ended upside.
• Avoid chasing the pro forma name post-close until first financing terms and runway are fully digested; use any post-announcement pop as an opportunity to fade if the equity trades above implied intrinsic value on thin volume.
• Monitor for financing syndicate completion and registration statement milestones as the key catalyst; any delay would be a strong signal to reduce exposure immediately because the trade is timing-sensitive rather than thesis-rich.